Dr. Patrick J. Geraghty, MD

Dr. Geraghty practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Geraghty's NPI, 1376560821, was assigned on July 17, 2006. Dr. Geraghty graduated from Northwestern University Feinberg Medical School in 1991. Dr. Geraghty holds Missouri license 115790.

Dr. Geraghty's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Geraghty also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Geraghty's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Geraghty is also affiliated with Missouri Baptist Medical Center. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Geraghty to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Geraghty practices, 6 sites in all. Vendor and product names are available with a free account.

Vascular surgery is Dr. Geraghty's primary specialty in the NPI Registry, under taxonomy code 2086S0129X. Dr. Geraghty is licensed in Missouri.

CMS data shows 2,316 Medicare services from Dr. Geraghty across 19 procedure codes in 2024, for 1,646 Medicare patients. Medicare paid $136,488 for them.

CMS counts 1,646 Medicare patients who saw Dr. Geraghty in 2024. The largest group is 65 to 74, with 732 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Geraghty's median patient age at 71, with 48% women.

In 2024, Dr. Geraghty wrote 242 Medicare Part D claims for 72 patients. 80% of them were for generic drugs. CMS names the drug for 179 of them, across 3 drugs with 11 or more claims each, at $30,465 in total drug cost. In 2023, CMS named 176 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Geraghty for performance year 2024, reported as part of a group. Dr. Geraghty accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 18 procedures of leg revascularization (restoring blood flow) by Dr. Geraghty, more than 77% of the clinicians it reports for that procedure.

Varicose vein removal: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links Dr. Geraghty to 1 clinical trial. Conditions studied include Chronic Limb-Threatening Ischemia and Peripheral Arterial Disease. Open Payments lists research payments to Dr. Geraghty that name 1 trial.

CMS Open Payments shows 343 general payments to Dr. Geraghty from 40 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 68% of the total. C. R. Bard, Inc. & Subsidiaries paid the most, $70,703. It also lists 5 research payments totaling $61,032 from 2016 to 2024, naming 1 clinical trial.

Dr. Geraghty graduated from Northwestern University Feinberg Medical School in 1991.